Desmopressin (DDAVP) results in a temporary impravement in hemostasis and is therefore a treatment option in patients with bleeding disorders. lt is more readily available and less expensive than treatment with coagulation factor concentrates, by which a patient's lacking coagulation factor is substituted.

This makes it an attractive treatment option especially for countries with limited resources. The overall aim of this thesis was to investigate the (side) effects and outcome of hemostatic treatment, specifically desmopressin in patients with bleeding disorders.

Additional Metadata
Keywords Desmopressin, Hemophilia
Promotor F.W.G. Leebeek (Frank) , M.J.H.A. Kruip (Marieke)
Publisher Erasmus University Rotterdam
Sponsor The studies in this thesis were financially supported by: CSL Behring (Prof. Heimburger award), Pfizer B.V. (unrestricted investigator initiated research grant). Printing of this thesis was kindly supported by: Pfizer B.V., Ferring, CSL Behring, Bayer Healthcare, European Technology for Business Ltd.
ISBN 978-94-6169-800-1
Persistent URL
Stoof, S.C.M. (2016, February 17). Effects and outcome of hemostatic treatment in bleeding disorders. Erasmus University Rotterdam. Retrieved from